U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed? – Video

Posted on by


U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed?
Our U.S. Stem Cell Clinic will perform outpatient procedures using a process in which we isolate a patient #39;s own stem cells from either their own adipose fat tissue or bone marrow. Approximately...

By: U.S. Stem Cell Clinic

Read the original:

U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed? - Video

U.S. Stem Cell Clinic: When should I expect to see results? – Video

Posted on by


U.S. Stem Cell Clinic: When should I expect to see results?
It is important to note that we are treating patients with their own adult stem cells, therefore each treatment and response is unique to that patient. No guarantee can be made of what results...

By: U.S. Stem Cell Clinic

See original here:

U.S. Stem Cell Clinic: When should I expect to see results? - Video

Most stem cell therapy at experimental stage: Scientist

Posted on by

New Delhi, April 11 (IANS): Though there are many stem cell therapies that are being explored, bone marrow transplant is the only one which has been tried and tested, a noted scientist has said.

Stem cell therapy is the use of stem cells to treat or prevent a disease or condition. Stem cells are undifferentiated cells of an organism which are capable of giving rise to indefinitely more cells of the same type, and from which certain other kinds of cells arise by differentiation.

"Most of the stem cell therapies like the ones which can successfully treat Parkinson's disease and methods of ortho-reconstruction are in experimental stages," noted cellular biologist Jyotsna Dhawan said in a special lecture on 'Stem cells: Myths and Realities' at the India International Centre (IIC) here Friday evening.

Dhawan, a senior scientist at the Centre for Cellular and Molecular Biology, Hyderabad, said stem cells are a potential source of repair of other tissues and can be very useful in treating genetic and inherited diseases. She said stem cells are specially useful in treating genetic disorders associated with blood like haemophilia and thalassemia.

"But, major ethical issues arise when embryonic stem cells (cells taken from a foetus) are used for therapy," she added.

On the many myths associated with stem cells, Dhawan said: "All these myths stem from the hope that we are able to tackle many of these diseases through stem cells".

Experiments are on to try and find cures for debilitating and terminal diseases like muscular dystrophy and cancer through stem cell therapy.

Stay updated wherever you go with Daijiworld.com and Daijiworld 24X7 tv channel mobile apps. CLICK HERE to download it for your device. (available on Android and IOS)

See more here:

Most stem cell therapy at experimental stage: Scientist

Regeneus hits key stem cell manufacturing milestone

Posted on by

(MENAFN - ProactiveInvestors)

Regeneus (ASX: RGS) has achieved a key milestone with the manufacture of its off-the-shelf stem cell therapy product Progenza for its First-in-Human trial for the treatment of osteoarthritis.

The company is on track to receive ethics approval and commence recruitment for the trial in the first-half of 2015.

Adding interest the company highlighted the benefit of using adipose or fat tissue over other tissue types by demonstrating the capacity to produce millions of therapeutic doses of Progenza from a single donor.

The production of commercial quantities of stem cells from a single donor is critical to maximise dose-to-dose consistency chief executive officer John Martin said.

This scale of production will minimise clinical trial and regulatory risks while reducing the cost of the final product.

One of the key advantages for manufacturing Progenza at industrial scale is that it uses stem cells sourced from adipose or fat tissue.

Adipose tissue is readily available from donors in large quantities and has significantly higher stem cells per gram of tissue than other tissue sources such as bone marrow or cord tissue.

Also adipose derived stem cells show greater capacity for expansion than stem cells from other tissue types.

Progenza adipose derived stem cells are adult stem cells they are not genetically modified like induced pluripotent stem cells (iPSC).

Read the original here:

Regeneus hits key stem cell manufacturing milestone

CryoStor Cell Preservation Selected For Phase III Clinical Trials of C-Cure Cell Therapy for Congestive Heart Failure

Posted on by

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (BioLife or the Company), today announced that Cardio3 BioSciences, a leader in engineered cell therapy with clinical programs initially targeting indications in cardiovascular disease and oncology, has embedded the Companys clinical grade CryoStor cryopreservation freeze media in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial to be conducted in the United States.

CHART-1 (Congestive Heart Failure Cardiopoietic Regenerative Therapy) is a patient prospective, controlled multi-centre, randomized, double-blinded Phase III clinical trial comparing treatment with C-Cure to a sham treatment. The trial has recruited 240 patients with chronic advanced symptomatic heart failure. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at nine months post-procedure.

Dr. Christian Homsy, CEO of Cardio3 BioSciences, commented on the selection of CryoStor by stating, We evaluated several possible freeze media formulations for our clinical cell therapy product development and manufacturing. CryoStor and BioLife best met our preservation efficacy, product and supplier quality, and customer support requirements.

As of January 2015, BioLife management estimates that the Companys CryoStor freeze media and HypoThermosol cell and tissue storage/shipping media have been incorporated into at least 175 customer clinical trials of novel cellular immunotherapies and other cell-based approaches for treating and possibly curing the leading causes of death and disorders throughout the world. Within the cellular immunotherapy segment of the regenerative medicine market, BioLife's products are embedded in the manufacturing, storage, and delivery processes of at least 75 clinical trials of chimeric antigen receptor T cells (CAR-T), T cell receptor (TCR), dendritic cell (DC), tumor infiltrating lymphocytes (TIL), and other T cell-based cellular therapeutics targeting solid tumors, hematologic malignancies, and other diseases and disorders. A large majority of the currently active private and publicly traded cellular immunotherapy companies are BioLife customers.

Mike Rice, BioLife Solutions CEO, remarked; We are honored to be able to supply our clinical grade CryoStor cell freeze media for Cardio3 Biosciences phase III clinical trials. Congestive heart failure is a leading cause of death and C-Cure is a novel and potentially life-saving, cell-based therapy that offers hope to millions of patients throughout the world. We are very well positioned to participate in the growth of the regenerative medicine market, with our products being used in at least 75 phase II and over 20 phase III clinical trials of new cell and tissue based products and therapies.

About Cardio3 Biosciences Cardio3 BioSciences is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiovascular disease and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA with the Mayo Clinic (MN, USA) and Dartmouth College (NH, USA). The Companys lead product candidate in cardiology is C-Cure, an autologous stem cell therapy for the treatment of ischemic heart failure. The Companys lead product candidate in oncology is CAR- NKG2D, an autologous CAR T-cell product candidate using NKG2D, a natural killer cell receptor designed to target ligands present on multiple tumor types, including ovarian, bladder, breast, lung and liver cancers, as well as leukemia, lymphoma and myeloma. Cardio3 BioSciences is also developing medical devices for enhancing the delivery of diagnostic and therapeutic agents into the heart (CCath) and potentially for the treatment of mitral valve defects. Cardio3 BioSciences shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD. To learn more about Cardio3 BioSciences, please visit c3bs.com

Read the original:

CryoStor Cell Preservation Selected For Phase III Clinical Trials of C-Cure Cell Therapy for Congestive Heart Failure

Transformation, Leadership and Spirituality in Medicine 2014 – Video

Posted on by


Transformation, Leadership and Spirituality in Medicine 2014
A Presentation Of Global Foundation For Ethics And Spiritual Health). To Register for 2015 Event please use the url below: http://events.r20.constantcontact.com/register/event?llr=cok8ctjab oeidk...

By: Global Foundation For Ethics And Spiritual Health

Read the rest here:

Transformation, Leadership and Spirituality in Medicine 2014 - Video